Related Experiment Video
Updated: Jul 18, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Tumor-specific genetic lesions and their influence on therapy in pediatric acute lymphoblastic leukemia
James R Downing1, Charles G Mullighan
1St. Jude Children's Research Hospital, 332 N. Lauderdale Street, Memphis, TN 38105, USA. James.downing@stjude.org
Abstract:
Pharmacogenomics has traditionally focused on the identification of inherited genetic differences that influence a patient's response to a specific therapeutic agent. These differences can range from inherited variability in the genes that affect drug absorption, distribution, intracellular transport, metabolism, and elimination, to variability in the genes that encode either the target of the drug or components of the pathway affected by the drug. The main goal of pharmacogenomics is to improve our understanding of how these variations, either individually or collectively, influence the therapeutic response. The genetic differences inherent within cancer cells constitute the other major variable in a patient's ultimate response to therapy. In this review, we provide an overview of high-throughput genomic methods that can be used to identify genetic lesions within cancer cells. These efforts will ultimately allow the identification of the full complement of genetic lesions that underlie the establishment and maintenance of the leukemic clone. The identification of these lesions should provide the bases for defining the molecular "Achilles heels" against which new targeted therapies can be developed.
Insights
Pharmacogenomics studies inherited genetic variations affecting drug response. This review explores high-throughput genomic methods to identify cancer-specific genetic lesions for developing targeted therapies.
Area of Science:
- Genomics
- Pharmacology
- Oncology
Background:
- Pharmacogenomics traditionally investigates inherited genetic variations influencing drug response, including drug metabolism and target pathways.
- Cancer cell genetic differences are crucial variables impacting therapeutic outcomes.
- Understanding these genetic factors is key to personalized medicine.
Purpose of the Study:
- To review high-throughput genomic methods for identifying genetic alterations in cancer cells.
- To elucidate the genetic underpinnings of leukemic clone establishment and maintenance.
- To provide a foundation for developing novel targeted therapies against cancer's molecular vulnerabilities.
Main Methods:
- Review of high-throughput genomic technologies.
- Analysis of genetic lesions in cancer cells.
- Integration of pharmacogenomic and cancer genomics data.
Main Results:
- High-throughput methods enable comprehensive identification of genetic lesions in cancer.
- These methods can reveal the complete set of genetic alterations driving leukemic clones.
- Potential for identifying molecular targets for new therapeutic strategies.
Conclusions:
- Genomic analysis of cancer cells is essential for understanding treatment response.
- Targeted therapies can be developed by exploiting identified molecular vulnerabilities.
- Pharmacogenomics and cancer genomics integration promises advancements in personalized cancer treatment.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:27Tumor Immunotherapy